STOCK TITAN

Morphic Holding Inc - MORF STOCK NEWS

Welcome to our dedicated news page for Morphic Holding (Ticker: MORF), a resource for investors and traders seeking the latest updates and insights on Morphic Holding.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Morphic Holding's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Morphic Holding's position in the market.

Rhea-AI Summary
Morphic Therapeutic announces the appointment of Simon Cooper, M.B.B.S., as Chief Medical Officer, bringing extensive experience in clinical development and immunology. Dr. Cooper's background includes successful leadership in autoimmune, inflammatory, cardiovascular, and pulmonary diseases, enhancing Morphic's capabilities in advancing MORF-057 for the treatment of inflammatory bowel disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.32%
Tags
management
-
Rhea-AI Summary
Morphic Therapeutic (MORF) announces participation in investor conferences, including panels and fireside chats, during March 2024. The company focuses on developing oral integrin therapies for chronic diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.02%
Tags
conferences
-
Rhea-AI Summary
Morphic Therapeutic (MORF) reports successful results from EMERALD-1 phase 2a trial of MORF-057 in ulcerative colitis, with positive clinical outcomes and financial stability. The company is progressing well with the EMERALD-2 phase 2b trial and anticipates starting the GARNET phase 2 trial for Crohn’s disease in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.04%
Tags
earnings
Rhea-AI Summary
Morphic Therapeutic (MORF) CEO Dr. Praveen Tipirneni returns in full capacity from medical leave and will present at the 42nd Annual J.P. Morgan Healthcare Conference. The company is focused on developing oral integrin therapies for serious chronic diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.77%
Tags
conferences
-
Rhea-AI Summary
Morphic Therapeutic (Nasdaq: MORF) announces participation in Jefferies London Healthcare Conference and Evercore ISI HealthCONx Conference, presenting on new oral integrin therapies for chronic diseases. Live webcasts available on company website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.54%
Tags
conferences
-
Rhea-AI Summary
Morphic Therapeutic reported positive Phase 2a data for MORF-057 in ulcerative colitis patients, with consistent efficacy and no safety signals. They also continued enrollment in the Phase 2b trial and ended Q3 with $725.1 million in cash.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.2%
Tags
earnings
Rhea-AI Summary
Morphic Therapeutic to discuss complete results from EMERALD-1 Phase 2a study of MORF-057 in ulcerative colitis
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.65%
Tags
conferences
-
Rhea-AI Summary
Morphic Holdings Inc. CEO takes medical leave of absence, expected to return after recovery. Executive team to continue day-to-day operations. No interruptions or changes expected. Company confident in pipeline and technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.99%
Tags
none
-
Rhea-AI Summary
Morphic Therapeutic announces positive results for MORF-057 in ulcerative colitis
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences clinical trial
Rhea-AI Summary
Morphic Therapeutic to participate in fireside chat at Wells Fargo Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.49%
Tags
none
Morphic Holding Inc

Nasdaq:MORF

MORF Rankings

MORF Stock Data

1.72B
36.80M
16.77%
91.69%
12.05%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Waltham

About MORF

oral integrin therapies for patients with immunological, fibrotic, neoplastic and vascular diseases. morphic tx is joining a three decade quest led by our scientific founder, tim springer, who initially discovered the integrin receptor family in the 1980s. this receptor family is an important drug target that has fueled the successful development of six injectable therapies approved for treatment of multiple sclerosis, ulcerative colitis, crohn's disease, plaque psoriasis, acute coronary syndrome and complications during percutaneous coronary intervention. despite blockbuster commercial success, integrins have remained out of reach as small molecule drugs...until now.